Although trametinib is known to be highly effective against BRAF/NRAS wild-type melanoma, its sensitivity in NF1-negative melanoma cell lines is comparable to that in NF1-expressing lines [32], suggesting that further research is required. Here, BRAF is linked to melanoma.